<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>694</number>
    <updateDate>2025-11-19T03:06:44Z</updateDate>
    <updateDateIncludingText>2025-11-19T03:06:44Z</updateDateIncludingText>
    <originChamber>Senate</originChamber>
    <originChamberCode>S</originChamberCode>
    <type>S</type>
    <introducedDate>2025-02-24</introducedDate>
    <congress>119</congress>
    <legislationUrl>https://www.congress.gov/bill/119th-congress/senate-bill/694</legislationUrl>
    <committees>
      <item>
        <systemCode>ssfi00</systemCode>
        <name>Finance Committee</name>
        <chamber>Senate</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Referred To</name>
            <date>2025-02-24T22:20:07Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <relatedBills>
      <item>
        <title>PLASMA Act</title>
        <congress>119</congress>
        <number>1476</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2025-02-21</actionDate>
          <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Identical bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2025-02-24</actionDate>
        <committees>
          <item>
            <systemCode>ssfi00</systemCode>
            <name>Finance Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Read twice and referred to the Committee on Finance.</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionDate>2025-02-24</actionDate>
        <text>Introduced in Senate</text>
        <type>IntroReferral</type>
        <actionCode>10000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>T000476</bioguideId>
        <fullName>Sen. Tillis, Thomas [R-NC]</fullName>
        <firstName>Thomas</firstName>
        <lastName>Tillis</lastName>
        <party>R</party>
        <state>NC</state>
        <middleName>Roland</middleName>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>K000377</bioguideId>
        <fullName>Sen. Kelly, Mark [D-AZ]</fullName>
        <firstName>Mark</firstName>
        <lastName>Kelly</lastName>
        <party>D</party>
        <state>AZ</state>
        <sponsorshipDate>2025-02-24</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>B001305</bioguideId>
        <fullName>Sen. Budd, Ted [R-NC]</fullName>
        <firstName>Ted</firstName>
        <lastName>Budd</lastName>
        <party>R</party>
        <state>NC</state>
        <sponsorshipDate>2025-04-08</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>P000145</bioguideId>
        <fullName>Sen. Padilla, Alex [D-CA]</fullName>
        <firstName>Alex</firstName>
        <lastName>Padilla</lastName>
        <party>D</party>
        <state>CA</state>
        <sponsorshipDate>2025-04-08</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
    </cosponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Blood and blood diseases</name>
          <updateDate>2025-07-17T17:25:05Z</updateDate>
        </item>
        <item>
          <name>Drug therapy</name>
          <updateDate>2025-07-17T17:25:05Z</updateDate>
        </item>
        <item>
          <name>Health care costs and insurance</name>
          <updateDate>2025-07-17T17:25:05Z</updateDate>
        </item>
        <item>
          <name>Manufacturing</name>
          <updateDate>2025-07-17T17:25:05Z</updateDate>
        </item>
        <item>
          <name>Medicare</name>
          <updateDate>2025-07-17T17:25:05Z</updateDate>
        </item>
        <item>
          <name>Prescription drugs</name>
          <updateDate>2025-07-17T17:25:05Z</updateDate>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
        <updateDate>2025-03-21T14:06:53Z</updateDate>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2025-02-24</actionDate>
        <actionDesc>Introduced in Senate</actionDesc>
        <updateDate>2025-08-18T19:08:45Z</updateDate>
        <cdata>
          <text>&lt;p&gt;&lt;strong&gt;Preserving Life-saving Access to Specialty Medicines in America Act or the PLASMA Act&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;This bill phases-in certain price adjustments for plasma-derived products under the Medicare prescription drug benefit's Manufacturer Discount Program.&lt;/p&gt;&lt;p&gt;Current law requires manufacturers of covered drugs under the Medicare prescription drug benefit to provide a 10% discount for covered drugs during the initial coverage phase (i.e., before a beneficiary reaches the out-of-pocket spending threshold) and a 20% discount during the catastrophic coverage phase (i.e., after a beneficiary reaches the out-of-pocket spending threshold).&amp;nbsp;&lt;/p&gt;&lt;p&gt;The bill phases-in discounts for plasma-derived products over several years, starting with a 1% discount in 2026 for both the initial and catastrophic coverage phases, and ending with a 10% discount beginning in 2030 for the initial coverage phase and a 20% discount beginning in 2032 for the catastrophic coverage phase.&lt;/p&gt;</text>
        </cdata>
      </summary>
    </summaries>
    <title>PLASMA Act</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <titleTypeCode>45</titleTypeCode>
        <title>PLASMA Act</title>
        <updateDate>2025-04-09T11:03:17Z</updateDate>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <titleTypeCode>101</titleTypeCode>
        <title>PLASMA Act</title>
        <updateDate>2025-03-20T03:23:18Z</updateDate>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <titleTypeCode>101</titleTypeCode>
        <title>Preserving Life-saving Access to Specialty Medicines in America Act</title>
        <updateDate>2025-03-20T03:23:18Z</updateDate>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <titleTypeCode>6</titleTypeCode>
        <title>A bill to amend title XVIII of the Social Security Act to provide a phase-in for plasma-derived products under the manufacturer discount program.</title>
        <updateDate>2025-03-20T03:18:33Z</updateDate>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Introduced in Senate</type>
        <date>2025-02-24T05:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-119s694is/xml/BILLS-119s694is.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2025-02-24</actionDate>
      <text>Read twice and referred to the Committee on Finance.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
